| |
Titel |
|
1e auteur |
|
| |
Treatment of steroid resistant grade II to IV acute GVHD by infusion of mesenchymal stroma cells expanded with human plasma and platelet lysate - a phase I/II study |
|
CM Mansilla Puerta |
|
| |
Apoptotic blebs from leukemic cells as a source of tumor associated antigen for monocyte-derived dendritic cell loading
|
|
J.M. Ruben |
|
| |
Association of disparities in known minor histocompatibility antigens with relapse-free survival and graft-versus-host-disease upon cancer treatment with allogeneic stem cell transplantation |
|
W.A. Hobo |
|
| |
Collateral Damage of Non-hematopoietic Tissue by Hematopoiesis-specific T Cells Results in GvHD During an Ongoing Profound GvL Reaction |
|
B van der Zouwen |
|
| |
DEVELOPMENT OF ANTIBODY RESPONSES AGAINST H-Y ANTIGENS AND THEIR X-VARIANTS AFTER ALLOGENEIC HEMATOPOEIETIC STEM CELL TRANSPLANTATION AND DONOR LYMPHOCYTE INFUSION
|
|
JC van der Griendt |
|
| |
Generation of allo-HLA restricted T-cells with potent B-cell reactivity using MHC tetramer pull down carries the risk of off-target reactivity |
|
L. Jahn |
|
| |
Improved outcome following Intensive Care Unit support within 100 days after allogeneic Haematopoietic Stem Cell Transplant |
|
M. van Vliet |
|
| |
Improving human monocyte-derived dendritic cell vaccines by lipid nanoparticle-mediated delivery of PD-L1 and PD-L2 siRNA |
|
W.A. Hobo |
|
| |
Multipotent Vδ2-negative γδT-cells after CMV-reactivation in allogeneic stem cell transplantation |
|
W.A. Scheper |
|
| |
Pre-clinical evaluation of ex vivo-generated natural killer cells as immunotherapeutic product against acute myeloid leukemia. |
|
J. Cany |
|
| |
Rapid identification and expression analysis of minor histocompatibility antigens by whole genome association scanning and microarray gene expression analysis
|
|
MJ Pont |
|
| |
The Aryl hydrocarbon Receptor antagonist StemRegenin1 promotes expansion of immature hematopoietic progenitors
|
|
L Duinhouwer |
|
| |
A Good Manufacturing Practice procedure to generate therapeutic numbers of highly pure anti-leukemic virus-specific T-cells |
|
M.M. van Loenen |
|
| |
B and T lymphocyte attenuator mediates inhibition of MiHA-specific CD8+ T cells in allogeneic stem cell transplantation patients |
|
WJ Norde |
|
| |
Decreased levels of circulating CCR6+CD161hiCD8+ T cells harboring cyclosporine resistance are associated with the development of graft-versus-host disease |
|
AB van der Waart |
|
| |
Identification of New Hematopoietic Minor Histocompatibility Antigen UTA2-1; Applicable in Antitumor Immunotherapy. |
|
R. Oostvogels |
|
| |
In vivo T-cell depletion using rabbit derived ATG leads to an increased EBV-PTLD risk due to an induced imbalance between B and T-cell recovery which is not seen after horse derived ATG or alemtuzumab |
|
I Jedema |
|
| |
Promising efficacy of combined inolimomab and etanercept in severe steroid-refractory acute graft-versus-host disease (aGVHD) |
|
A Liefferink |
|
| |
The chemokine receptor CXCR3 is required for the efficient recruitment of bone marrow-resident memory T cells to inflamed tissues |
|
R van der Voort |
|
| |
Occurence of T cells specific for the Aspergillus proteins Crf1 and Catalase1 in SCT patients recovering from invasive aspergillosis. |
|
H Jolink |
|
| |
Titel |
|
1e auteur |
|
| |
ACETYLATION OF C/EBPε IS FUNCTIONALLY IMPORTANT DURING NEUTROPHIL DEVELOPMENT. |
|
M Bartels |
|
| |
Erythropoiesis and globin switching in compound Klf1-Bcl11a mutant mice |
|
F. Esteghamat |
|
| |
Identification of novel cytokines and chemokines that induce HSC expansion |
|
A. Ocal Sahin |
|
| |
Interferon-gamma Impairs The Self-Renewal Of Hematopoietic Stem Cells |
|
A.M. de Bruin |
|
| |
Matrix protein βig-h3 function in hematopoietic and stromal cells |
|
S.E. Klamer |
|
| |
The extracellular matrix protein Slit3 promotes erythropoiesis.
|
|
K. Brussen |
|
| |
Central memory CD8 T cells regulate hematopoietic stem cell function |
|
C.I. Brandao |
|
| |
Developing thymic regenerative therapy by generating thymic epithelial precursor cells from induced pluripotent stem cells |
|
E Vroegindeweij |
|
| |
Polycomb Group Complex 1 Composition determines Hematopoietic Stem Cell fate |
|
V. Radulovic |
|
| |
PRC1 complex composition dictates locus-specific polycomb-mediated repression in human stem/progenitor cells |
|
V. van den Boom |
|
| |
Regulation of erythrocyte shape through LYN-induced tyrosine phosphorylation and downstream events. |
|
E Ovchynnikova |
|
| |
Regulation of membrane complex - cytosceleton interactions in erythrocytes. The role of the Band 3 complexes |
|
E.V. Ovchynnikova |
|
| |
The E3 ubiquitin ligase Triad1 prevents chromosomal missegregation by regulating the checkpoint kinase Bub1 |
|
D Monteferrario |
|
| |
The transcription factor MEIS1 regulates early erythroid and megakaryocytic cell fate |
|
S. Zeddies |
|
| |
Titel |
|
1e auteur |
|
| |
High miR-212 expression predicts for better survival in cytogenetically and molecularly heterogeneous AML |
|
SMS Sun |
|
| |
A hazard based flow cytometric scoring system for the prognosis of myelodysplastic syndromes |
|
C Alhan |
|
| |
CEBPα Is a Transcriptional Repressor of T-Cell Related Genes Explaining the Myeloid/T-Lymphoid Features of CEBPα-Silenced AML |
|
E Taskesen |
|
| |
Constitutional t(16;21)(p13;q22) as a novel pathogenomic mechanism in a series of three new RUNX1 mutated FPD/AML pedigrees: implications for diagnostics |
|
A. Buijs |
|
| |
Exome Sequencing of Late Recurrence T-Cell Acute Lymphoblastic Leukemia in Children Confirms Second Leukemia and Exposes Predisposition Candidate Genes |
|
E Waanders |
|
| |
High GATA-2 expression is a poor prognostic marker in pediatric Acute Myeloid Leukemia |
|
M. Luesink |
|
| |
MicroRNA Expression Profiling of Hematopoietic and Leukemic Stem Cells in Acute Myeloid Leukemia
|
|
D.C. de Leeuw |
|
| |
Mutations in TET2 and IDH in patients with acute myeloid leukemia perturb a common epigenetic pathway resulting in decreased 5-hydroxymethylcytosine levels |
|
M.G. Aslanyan |
|
| |
Mutations in TET2 and IDH in patients with acute myeloid leukemia perturb a common epigenetic pathway resulting in decreased 5-hydroxymethylcytosine levels |
|
M.G. Aslanyan |
|
| |
PCR-based detection of PLZF-RARα fusion gene in Iranian patients with
acute promyelocytic leukemia morphology |
|
Mohammad Araghi |
|
| |
Plasma Membrane proteomics on human HSCs/MPPs/LSCs. |
|
F. Bonardi` |
|
| |
Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by allogeneic hematopoietic stem cell transplantation: a retrospective study on behalf of the MDS subcommittee of the Chronic Leukaemia Working Party of the EBMT |
|
E. Cremers |
|
| |
Targeting of Acute Myeloid Leukemia (stem) cells by anti-CLEC12A Antibody-Drug-Conjugates and Bispecific CLL-1xCD3 BiTE Antibody |
|
P. Noordhuis |
|
| |
The Origin and Nature of Tightly Clustered BTG1 Deletions in Precursor B-cell Acute Lymphoblastic Leukemia Support a Model of Multiclonal Evolution |
|
B. Scheijen |
|
| |
The role of the class III PI3K Vps34 in regulation of normal and malignant hematopoiesis
|
|
R. Polak |
|
| |
Therapeutic target identification specific for leukemic stem cells of Acute Myeloid Leukemia |
|
H.J.M.P. Verhagen |
|
| |
Towards immunotherapy of acute myeloid leukemia with allogeneic NK cells generated from umbilical cord blood hematopoietic progenitor cells |
|
B. N. Hangalapura |
|
| |
miR34-a and POXP1 are involved in a negative feedback loop responding to double-stranded DNA breaks in developing B cells |
|
K Ochodnicka |
|
| |
CITED2 Modulates Differentiation and Proliferation of Normal and Leukemic Hematopoietic Stem and Progenitor Cells Downstream of PU.1.
|
|
H. Schepers |
|
| |
Combination of CD34/CD38 Immunophenotypes and Side Population (SP) reveals the Putative Leukemia Stem Cell/Leukemia Initiating Cell in Acute Myeloid Leukemia |
|
F. Wouters |
|
| |
Comparison of high resolution microarray-based genomic profiling and multiplex ligation-dependent probe amplification (MLPA) for the detection of clinically relevant genetic lesions in acute lymphoblastic leukemia |
|
A Simons |
|
| |
Gene expression profiling, high-density genome-wide genotyping and copy number analyses of adult acute lymphoblastic leukemia. |
|
M.A. Sanders |
|
| |
GFI1 is a direct target of the oncofusion protein AML1-ETO in acute myeloid leukemia |
|
J Israel |
|
| |
High class II-associated invariant chain peptide (CLIP) expression on residual leukemic cells is associated with increased relapse risk in acute myeloid leukemia |
|
W van den Ancker |
|
| |
Mouse versus human extrinsic cues dictate transformation potential in BCR-ABL/BMI1-induced leukemia in human xenograft models.
|
|
P.S Sontakke |
|
| |
New multiparameter approach for the identification of leukemic stem cells in acute myeloid leukemia patients.
|
|
W Zeijlemaker |
|
| |
NF-κB and MCL-1 Are Important Determinants for the Effectiveness of Bortezomib In CD34+ AML Cells |
|
M.C.J. Bosman |
|
| |
Sensitivity of Pediatric Acute Leukemia Cells to Bortezomib and Epoxyketone-Based Proteasome Inhibitors: Correlations with Proteasome Subunit Expression |
|
D. Niewerth |
|
| |
SNP-based genomic profiling and karyotyping as diagnostic tools for the identification of clinically relevant chromosomal abnormalities in MDS |
|
M-JPL Stevens-Kroef |
|
| |
Genetic defects in PRC2 components other than EZH2 are not common in myeloid malignancies |
|
L.I. Kroeze |
|
| |
Heck of a job there, it absloutely helps me out. |
|
|
|
| |
Titel |
|
1e auteur |
|
| |
Are we on the right track?
Incidence, survival and mortality from plasma cell malignancies in the Netherlands in the last two decades: results from a population based study.
|
|
S.G.R. Verelst |
|
| |
Comparison of screening tools MUST and SNAQ in hematopoietic stem cell transplantation patients: an explorative study. |
|
A van Wegberg |
|
| |
Evaluation of a Patient Information Website concerning Long-term Adverse Effects following Hodgkin Lymphoma treatment |
|
GCC Sombroek |
|
| |
High Dose (HD-AraC) vs Standard Dose Cytosine Arabinoside (SD-AraC) during Induction and IL-2 vs Observation after Consolidation/Autologous stem cell transplantation in patients with Acute Myelogenous Leukemia (AML): Final report of the AML-12 randomized phase III trial of EORTC and GIMEMA Leukemia Groups on the value of High Dose AraC |
|
R. Willemze |
|
| |
Implementation of plerixafor in Dutch leukapheresis departments |
|
R.R.D. Gahar |
|
| |
Optimal treatment sequencing in patients with multiple myeloma not eligible for stem cell transplantation: modelling as a solution to questions that trials can’t answer? |
|
M van Agthoven |
|
| |
Patient participation during medical encounters in lymphoma cancer; patients’ preferences and needs |
|
I.R. van Bruinessen |
|
| |
Persistent fatigue among (long-term) non-Hodgkin lymphoma survivors: results from the longitudinal population-based PROFILES registry in the South of the Netherlands |
|
S. Oerlemans |
|
| |
Preliminary Results from a Phase III Trial of Imatinib Versus Imatinib in Combination with Cytarabine in Patients with First Chronic Phase Myeloid Leukemia |
|
N Thielen |
|
| |
Quantitative in-vivo monitoring of bone formation in multiple myeloma patients following treatment with bortezomib: a pilot study. |
|
JC Regelink |
|
| |
Rituximab as maintenance treatment for follicular lymphoma in daily practice in the Netherlands: A population based study |
|
H.M. Blommestein |
|
| |
The direct treatment costs for patients with acute myeloid leukemia
|
|
A. Leunis |
|
| |
Treatment with Lenalidomide in myelodysplastic syndromes with 5q deletion: results from the Dutch named patient program (NPP) |
|
I Abouyahya |
|
| |
Alemtuzumab treatment can affect CD52 positive as well as CD52 negative GPI-deficient Sézary cells allowing long-term disease control. |
|
CJM Halkes |
|
| |
Diminished Asparaginase Turnover Due to a Germline Mutation in Cathepsin B |
|
L van der Meer |
|
| |
Does 18F-fluorodeoxyglucose Outperform 18F-fluorothymidine When Using Positron Emission Tomography in Predicting Transformation of Indolent Non-Hodgkin’s Lymphoma |
|
M.J. Wondergem |
|
| |
Endocrine late sequelae in long-term survivors of childhood non-Hodgkin lymphoma |
|
M van Waas |
|
| |
R-DHAP Immuno-Chemotherapy Is An Effective Remission-Induction Treatment for Fludarabine Refractory CLL Patients and Allows the Majority to Proceed to Allogeneic Stem Cell Transplantation. Results of the Planned Interim Analysis of the Dutch-Belgian Prospective Multicenter HOVON88 Trial |
|
M van Gelder |
|
| |
The Impact of Prophylactic Fresh Frozen Plasma On Venous Thromboembolism in Adults Treated for Acute Lymphoblastic Leukemia |
|
MN Lauw |
|
| |
Titel |
|
1e auteur |
|
| |
The molecular targets of Dasatinib involved in conferring CD40-mediated drug resistance in chronic lymphocytic leukemia
|
|
C.R. Geest |
|
| |
Bortezomib restores defective apoptosis by upregulation of Noxa in Enteropathy-associated T-cell Lymphoma |
|
LR de Baaij |
|
| |
CMV-secific T cell function is not impaired in CLL |
|
G.D. Te Raa |
|
| |
Identification of miR-155 targets in Burkitt lymphoma |
|
I. Slezak-Prochazka |
|
| |
Induction of TAp73 expression by platinum-based compounds to overcome drug resistance in p53 dysfunctional chronic lymphocytic leukemia |
|
S H Tonino |
|
| |
Loss of the tumor suppressor CYLD causes enhanced NF-kappaB and Wnt/b-catenin signaling in multiple myeloma and confers drug resistance |
|
H. van Andel |
|
| |
Microenvironment Shields Myeloma from Adoptive Immunotherapy by Cell Adhesion Mediated Immune Resistance (CAM-IR) |
|
S.J. de Haart |
|
| |
Molecular dissection of signals provided by activated T cells to CLL cells indicates major role for IL-21 and CD40 in controlling proliferation and chemoresistance |
|
MF Pascutti |
|
| |
Multiple HLA class I and II associations in classic Hodgkin lymphoma and EBV status defined subgroups
|
|
Kushi Kushekhar |
|
| |
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia |
|
MFM de Rooij |
|
| |
The forkhead transcription factor FOXP1 represses human plasma cell differentiation |
|
M van Keimpema |
|
| |
Toll-like receptor expression profile of human myeloma derived cell lines |
|
J. Abdi |
|
| |
Towards Personalized Medicine Using a Novel Preclinical Model: Identifying Daratumumab as Effective Treatment for Multiple Myeloma |
|
GWJ Groen |
|
| |
A High-Risk Survival Signature for Multiple Myeloma |
|
R. Kuiper |
|
| |
APRIL is present in the microenvionment of CLL, and affects disease progression in the TCL-1 transgenic mouse model |
|
JG Schot |
|
| |
Expression and functional studies of IGF1R tyrosine kinase in Hodgkin lymphoma
|
|
L Zheng |
|
| |
Expression of c-Met in tumor cells correlates with favorable outcome in classical Hodgkin lymphoma |
|
W.J. Plattel |
|
| |
hsTRAIL/Apo2L-Induced Apoptosis in Enteropathy-Associated T-Cell Lymphoma |
|
M. Radersma |
|
| |
Identification of a Novel B-CLL Subset Expressing Mutated Stereotypic B-Cell Receptors with Specificity for Yeast Mannan |
|
R Hoogeboom |
|
| |
Is there a germinal centre-like and activated B-cell like diffuse large B-cell lymphoma miRNA profile? |
|
JL Robertus |
|
| |
Synergistic Action of the Human Inhibitory KIR Antibody IPH2102, and the Human CD38 Antibody Daratumumab to Enhance the Lysis of Primary Multiple Myeloma (MM) Cells in the Bone Marrow Mononuclear Cells (MNCs) from Myeloma Patients. |
|
I.S. Nijhof |
|
